Regency Capital Management Inc. DE Has $2.94 Million Holdings in Aura Biosciences, Inc. $AURA

Regency Capital Management Inc. DE cut its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 12.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 538,584 shares of the company’s stock after selling 74,105 shares during the period. Regency Capital Management Inc. DE’s holdings in Aura Biosciences were worth $2,935,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Tower Research Capital LLC TRC grew its stake in shares of Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after purchasing an additional 2,104 shares during the period. ProShare Advisors LLC acquired a new stake in shares of Aura Biosciences during the fourth quarter worth $59,000. Water Island Capital LLC acquired a new stake in shares of Aura Biosciences during the third quarter worth $64,000. 49 Wealth Management LLC acquired a new stake in shares of Aura Biosciences during the third quarter worth $66,000. Finally, Invesco Ltd. acquired a new stake in shares of Aura Biosciences during the second quarter worth $76,000. 96.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AURA has been the subject of a number of recent analyst reports. HC Wainwright upped their price objective on shares of Aura Biosciences from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Leerink Partners set a $17.00 price objective on shares of Aura Biosciences in a research report on Tuesday, May 12th. Weiss Ratings cut shares of Aura Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. Finally, Wall Street Zen upgraded shares of Aura Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $20.50.

Aura Biosciences Stock Down 1.2%

AURA opened at $6.80 on Friday. Aura Biosciences, Inc. has a 12 month low of $4.73 and a 12 month high of $9.53. The company has a fifty day simple moving average of $7.24 and a 200 day simple moving average of $6.29. The stock has a market cap of $703.05 million, a P/E ratio of -3.91 and a beta of 0.39.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). On average, equities research analysts expect that Aura Biosciences, Inc. will post -1.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Matrix Capital Management Comp sold 6,922,870 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $5.64, for a total value of $39,044,986.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Conor Kilroy sold 11,738 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $7.02, for a total transaction of $82,400.76. Following the completion of the transaction, the insider directly owned 217,835 shares of the company’s stock, valued at approximately $1,529,201.70. The trade was a 5.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.30% of the stock is currently owned by corporate insiders.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.